Revolution Medicines, INC Form 4 insider transactions

Director Flavia Borellini reports acquisition of 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.

Director Elizabeth Anderson reports acquiring shares and stock options in Revolution Medicines, Inc.

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,950 shares of common stock on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Jack Anders, CFO of Revolution Medicines, sold 1,893 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,415 shares of common stock on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,349 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,757 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.

Wei Lin, Chief Medical Officer of Revolution Medicines, sold 5,589 shares of common stock on June 17, 2024, to cover withholding taxes related to the vesting of restricted stock units.

Revolution Medicines CEO Mark Goldsmith exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan, while also transferring shares into a family trust.

Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on May 21, 2024, under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' CFO, Jack Anders, exercised stock options and sold shares on May 3, 2024, under a pre-arranged 10b5-1 trading plan.

Revolution Medicines CEO Mark Goldsmith sold shares of common stock on April 10, 2024, under a pre-arranged 10b5-1 trading plan.

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on April 10, 2024, under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on March 27, 2024, under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,252 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 2,123 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 2,914 shares of common stock on March 18, 2024, to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).

Mark A. Goldsmith, CEO of Revolution Medicines, sold shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,261 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports the acquisition of 41,000 shares of common stock and 143,500 stock options.

Mark Goldsmith, CEO of Revolution Medicines, reports the acquisition of 90,000 common stock shares and 314,000 stock options, alongside adjustments to existing holdings.

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 21,000 shares of common stock and 73,500 stock options.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired 51,400 shares of common stock and 179,900 stock options on March 1, 2024.

Jack Anders, CFO of Revolution Medicines, reports acquiring 26,400 shares of common stock and 92,400 stock options on March 1, 2024.

Xiaolin Wang, an officer at Revolution Medicines, acquired shares and stock options in the company on March 1, 2024.